These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22231327)

  • 1. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.
    Teng PR; Lane HY
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E16-7. PubMed ID: 22231327
    [No Abstract]   [Full Text] [Related]  

  • 2. Lower risk for body weight gain and better control of appetite after switching risperidone to paliperidone in a schizoaffective patient.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):E36-7. PubMed ID: 24763786
    [No Abstract]   [Full Text] [Related]  

  • 3. Possible paliperidone-induced neuroleptic malignant syndrome: a case report.
    Özdemir A; Aksoy-Poyraz C; Kılıç-Yener E
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):E22-3. PubMed ID: 23037666
    [No Abstract]   [Full Text] [Related]  

  • 4. Catatonia and encephalopathy associated with paliperidone palmitate.
    Coffey MJ
    J Clin Psychopharmacol; 2012 Apr; 32(2):284-5. PubMed ID: 22388156
    [No Abstract]   [Full Text] [Related]  

  • 5. Paliperidone-induced neuroleptic malignant syndrome.
    Nayak RB; Bhogale GS; Patil NM; Chate SS; Pandurangi AA; Shetageri VN
    J Neuropsychiatry Clin Neurosci; 2011; 23(1):E14-5. PubMed ID: 21304113
    [No Abstract]   [Full Text] [Related]  

  • 6. Possible neuroleptic malignant syndrome associated with paliperidone.
    Duggal HS
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):477-8. PubMed ID: 18070861
    [No Abstract]   [Full Text] [Related]  

  • 7. Possible neuroleptic malignant syndrome during paliperidone administration: a case report.
    Mantas C; Kalabokis G; Goulia P; Tourlakopoulos A; Hyphantis T; Mavreas V
    J Clin Psychopharmacol; 2010 Feb; 30(1):89-91. PubMed ID: 20075663
    [No Abstract]   [Full Text] [Related]  

  • 8. Two cases of risperidone-induced neuroleptic malignant syndrome.
    Dave M
    Am J Psychiatry; 1995 Aug; 152(8):1233-4. PubMed ID: 7542837
    [No Abstract]   [Full Text] [Related]  

  • 9. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.
    Han C; Lee SJ; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):650-1. PubMed ID: 21163319
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroleptic malignant syndrome with risperidone.
    Levin GM; Lazowick AL; Powell HS
    J Clin Psychopharmacol; 1996 Apr; 16(2):192-3. PubMed ID: 8690838
    [No Abstract]   [Full Text] [Related]  

  • 11. Risperidone and NMS?
    Murray S; Haller E
    Psychiatr Serv; 1995 Sep; 46(9):951. PubMed ID: 7583513
    [No Abstract]   [Full Text] [Related]  

  • 12. Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents.
    Zalsman G; Lewis R; Konas S; Loebstein O; Goldberg P; Burguillo F; Nahshoni E; Munitz H
    Int J Adolesc Med Health; 2004; 16(2):179-82. PubMed ID: 15266995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone/paliperidone induced neutropenia and lymphopenia.
    Raj V; Druitt T; Purushothaman S; Dunsdon J
    Aust N Z J Psychiatry; 2013 Mar; 47(3):291-2. PubMed ID: 22984110
    [No Abstract]   [Full Text] [Related]  

  • 14. Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to paliperidone.
    Hsu WY; Chiu NY
    J Clin Psychopharmacol; 2013 Oct; 33(5):712-3. PubMed ID: 23899637
    [No Abstract]   [Full Text] [Related]  

  • 15. Risperidone-induced neuroleptic malignant syndrome.
    Webster P; Wijeratne C
    Lancet; 1994 Oct; 344(8931):1228-9. PubMed ID: 7523815
    [No Abstract]   [Full Text] [Related]  

  • 16. Two cases of risperidone-induced neuroleptic malignant syndrome.
    Singer S; Richards C; Boland RJ
    Am J Psychiatry; 1995 Aug; 152(8):1234. PubMed ID: 7542838
    [No Abstract]   [Full Text] [Related]  

  • 17. Risperidone-induced neuroleptic malignant syndrome: a case report and review.
    Meterissian GB
    Can J Psychiatry; 1996 Feb; 41(1):52-4. PubMed ID: 8919425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone.
    Suzuki Y; Fukui N; Watanabe J; Ono S; Sugai T; Tsuneyama N; Saito M; Inoue Y; Someya T
    Hum Psychopharmacol; 2012 Jan; 27(1):39-42. PubMed ID: 22144033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical neuroleptic malignant syndrome associated with iloperidone administration.
    Guanci N; Aggarwal R; Schleifer S
    Psychosomatics; 2012; 53(6):603-5. PubMed ID: 23157999
    [No Abstract]   [Full Text] [Related]  

  • 20. Manic symptoms during a switch from risperidone to paliperidone: a case report.
    Yang FW; Liang CS
    J Neuropsychiatry Clin Neurosci; 2011; 23(3):E29. PubMed ID: 21948917
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.